Pharmacotherapy in Children and Adolescents at Clinical-High Risk for Psychosis and Bipolar Disorder

Pharmacopsychiatry

Volumn 49, Issue 6, 2016, Pages 229-244

  Lambert, M ^a   Niehaus, V ^a   Correll, C ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

bipolar disorder; early intervention; high risk; prodrome; schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ADOLESCENT DISEASE; ARTICLE; BIPOLAR DISORDER; CHILDHOOD DISEASE; COMORBIDITY; DRUG EFFICACY; DRUG SAFETY; DRUG THERAPY; DRUG TOLERABILITY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; PSYCHOTHERAPY; RISK FACTOR; SYSTEMATIC REVIEW; ADOLESCENT; CHILD; CLINICAL TRIAL (TOPIC); DIET THERAPY; PSYCHOTIC DISORDERS;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CHILD; CLINICAL TRIALS AS TOPIC; HUMANS; PSYCHOTIC DISORDERS;

EID: 84991221472     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0042-116668     Document Type: Article

References (145)

1. Woodberry K A Shapiro D I Bryant C et al. Progress and future directions in research on the psychosis prodrome: a review for clinicians Harv Rev Psychiatry 2016 24 87 103
2. Martin D J Smith D J Is there a clinical prodrome of bipolar disorder? A review of the evidence Expert Rev Neurother 2013 13 89 98
3. Kessler R C Angermeyer M Anthony J C et al. Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization’s World Mental Health Survey Initiative World Psychiatry 2007 6 168 176
4. Delespaul P H de consensusgroep EPA Consensus regarding the definition of persons with severe mental illness and the number of such persons in the Netherlands Tijdschr Psychiatr 2013 55 427 438
5. Fleischhacker W W Cetkovich-Bakmas M De Hert M et al. Comorbid somatic illness in patients with severe mental disorders: Clinical, policy, and research challenges J Clin Psychiatry 2008 69 514 519
6. Laursen T M Nordentoft M Mortensen P B Excess early mortality in schizophrenia Annu Rev Clin Psychol 2014 10 425 448
7. Hayes J F Miles J Walters K et al. A systematic review and meta-analysis of premature mortality in bipolar affective disorder Acta Psychiatr Scand 2015 131 417 425
8. Walker E R McGee R E Druss B G Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis JAMA Psychiatry 2015 72 334 341
9. Gore F M Bloem P J Patton G C et al. Global burden of disease in young people aged 10-24 years: a systematic analysis Lancet 2011 377 2093 2102
10. Vos T Flaxman A D Naghavi M et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 2012 380 2163 2196
11. Gustavsson A Svensson M Jacobi F et al. Cost of disorders of the brain in Europe 2010 European Neuropsychopharmacology 2011 21 718 779
12. Merikangas K R Akiskal H S Angst J et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication Arch Gen Psychiatry 2007 64 543 552
13. Correll C U Hauser M Auther A M et al. Research in people with psychosis risk syndrome: a review of the current evidence and future directions J Child Psychol Psychiatry 2010 51 390 431
14. Schmidt S J Schultze-Lutter F Schimmelmann B G et al. EPA guidance on the early intervention in CHR states of psychoses Eur Psychiatry 2015 30 388 404
15. Schultze-Lutter F Michel C Schmidt S J et al. EPA guidance on the early detection of CHR states of psychoses Eur Psychiatry 2015 30 405 416
16. Fusar-Poli P Cappucciati M Rutigliano G et al. At risk or not at risk? A meta-analysis of the prognostic accuracy of psychometric interviews for psychosis prediction World Psychiatry 2015 14 322 332
17. Carpenter W T Attenuated psychosis syndrome: need for debate on a new disorder Psychopathology 2014 47 287 291
18. Jääskeläinen E Haapea M Rautio N et al. Twenty years of schizophrenia research in the Northern Finland birth cohort 1966: a systematic review Schizophr Res Treatment 2015 2015 524875
19. Cannon T D Cadenhead K Cornblatt B et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America Arch Gen Psychiatry 2008 65 28 37
20. Ruhrmann S Schultze-Lutter F Salokangas R K et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study Arch Gen Psychiatry 2010 67 241 251
21. Cornblatt B A Carrión R E Auther A et al. Psychosis prevention: a modified clinical high risk perspective from the Recognition and Prevention (RAP) Program Am J Psychiatry 2015 172 986 984
22. Lim J Rekhi G Rapisarda A et al. Impact of psychiatric comorbidity in individuals at ultra-high risk of psychosis - Findings from the Longitudinal Youth at Risk Study (LYRIKS) Schizophr Res 2015 164 8 14
23. Lambert M Correll C Should antipsychotics be used in prodromal stages of schizophrenia to prevent psychosis? Pro Nervenarzt 2015 86 1420 1423
24. Bechdolf A Nelson B Cotton S M et al. A preliminary evaluation of the validity of at-risk criteria for bipolar disorders in help-seeking adolescents and young adults J Affect Disord 2010 127 316 320
25. Bechdolf A Ratheesh A Cotton S M et al. The predictive validity of bipolar at-risk (prodromal) criteria in help-seeking adolescents and young adults: a prospective study Bipolar Disord 2014 16 493 504
26. Leopold K Ritter P Correll C U et al. Risk constellations prior to the development of bipolar disorders: rationale of a new risk assessment tool J Affect Disord 2012 136 1000 1010
27. Correll C U Olvet D M Auther A M et al. The Bipolar Prodrome Symptom Interview and Scale-Prospective (BPSS-P): description and validation in a psychiatric sample and healthy controls Bipolar Disord 2014 16 505 522
28. Faedda G L Serra G Marangoni C et al. Clinical risk factors for bipolar disorders: a systematic review of prospective studies J Affect Disord 2014 168 314 321
29. Hunt J Schwarz C M Nye P et al. Is there a bipolar prodrome among children and adolescents? Curr Psychiatry Rep 2016 18 35
30. Rios A C Noto M N Rizzo L B et al. Early stages of bipolar disorder: characterization and strategies for early intervention Rev Bras Psiquiatr 2015 37 343 349
31. Fusar-Poli P Bonoldi I Yung A R et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk Arch Gen Psychiatry 2012 69 220 229
32. Fusar-Poli P Nelson B Valmaggia L et al. Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis Schizophr Bull 2014 40 120 131
33. Klosterkötter J Hellmich M Steinmeyer E M et al. Diagnosing schizophrenia in the initial prodromal phase Arch Gen Psychiatry 2001 58 158 164
34. Matheson S L Shepherd A M Laurens K R et al. A systematic meta-review grading the evidence for non-genetic risk factors and putative antecedents of schizophrenia Schizophr Res 2011 133 133 142
35. Ruhrmann S Schultze-Lutter F Schmidt S J et al. Prediction and prevention of psychosis: current progress and future tasks Eur Arch Psychiatry Clin Neurosci 2014 264 01 9 16
36. Koutsouleris N Borgwardt S Meisenzahl E M et al. Disease prediction in the at-risk mental state for psychosis using neuroanatomical biomarkers: results from the FePsy study Schizophr Bull 2012 38 1234 1246
37. Koutsouleris N Davatzikos C Bottlender R et al. Early recognition and disease prediction in the at-risk mental states for psychosis using neurocognitive pattern classification Schizophr Bull 2012 38 1200 1215
38. Nieman D H Ruhrmann S Dragt S et al. Psychosis prediction: stratification of risk estimation with information-processing and premorbid functioning variables Schizophr Bull 2013 40 1482 1490
39. Marshall M Rathbone J Early intervention for psychosis Cochrane Database Syst Rev 2011 15 CD004718
40. Power L Polari A R Yung A R et al. Distress in relation to attenuated psychotic symptoms in the ultra-high-risk population is not associated with increased risk of psychotic disorder Early Interv Psychiatry 2016 10 258 262
41. Rapado-Castro M McGorry P D Yung A et al. Sources of clinical distress in young people at ultra high risk of psychosis Schizophr Res 2015 165 15 21
42. Yang L H Link B G Ben-David S et al. Stigma related to labels and symptoms in individuals at clinical high-risk for psychosis Schizophr Res 2015 168 9 15
43. Bechdolf A Thompson A Nelson B et al. Experience of trauma and conversion to psychosis in an ultra-high-risk (prodromal) group Acta Psychiatr Scand 2010 121 377 384
44. Yung A R Cotter J Wood S J et al. Childhood maltreatment and transition to psychotic disorder independently predict long-term functioning in young people at ultra-high risk for psychosis Psychol Med 2015 45 3453 3465
45. Kraan T van Dam D S Velthorst E et al. Childhood trauma and clinical outcome in patients at ultra-high risk of transition to psychosis Schizophr Res 2015 169 193 198
46. Kraan T Velthorst E Smit F et al. Trauma and recent life events in individuals at ultra high risk for psychosis: review and meta-analysis Schizophr Res 2015 161 143 149
47. Kessler R C McLaughlin K A Green J G et al. Childhood adversities and adult psychopathology in the WHO World Mental Health Surveys Br J Psychiatry 2010 197 378 385
48. McLaughlin K A Greif Green J Gruber M J et al. Childhood adversities and first onset of psychiatric disorders in a national sample of US adolescents Arch Gen Psychiatry 2012 69 1151 1160
49. McLaughlin K A Green J G Gruber M J et al. Childhood adversities and adult psychiatric disorders in the national comorbidity survey replication II: associations with persistence of DSM-IV disorders Arch Gen Psychiatry 2010 67 124 132
50. Conrad A M Lewin T J Sly K A Ten-year audit of clients presenting to a specialised service for young people experiencing or at increased risk for psychosis BMC Psychiatry 2014 14 318
51. Kraan T Velthorst E Koenders L et al. Cannabis use and transition to psychosis in individuals at ultra-high risk: review and meta-analysis Psychol Med 2016 6 673 681
52. Buchy L Cadenhead K S Cannon T D et al. Substance use in individuals at clinical high risk of psychosis Psychol Med 2015 45 2275 2284
53. Skjelstad D V Malt U F Holte A Symptoms and signs of the initial prodrome of bipolar disorder: a systematic review J Affect Dis 2010 126 1 13
54. Correll C U Hauser M Penzner J B et al. Type and duration of subsyndromal symptoms in youth with bipolar I disorder prior to their first manic episode Bipolar Disord 2014 16 478 492
55. Noto M N Noto C Caribé A C et al. Clinical characteristics and influence of childhood trauma on the prodrome of bipolar disorder Rev Bras Psiquiatr 2015 37 280 288
56. Zeschel E Correll C U Haussleiter I S The bipolar disorder prodrome revisited: Is there a symptomatic pattern? J Affect Disord 2013 151 551 560
57. Faedda G L Marangoni C Serra G et al. Precursors of bipolar disorders: a systematic literature review of prospective studies J Clin Psychiatry 2015 76 614 624
58. Singh M K Is there validity to the bipolar prodrome? J Clin Psychiatry 2015 76 655 656
59. Benarous X Consoli A Milhiet V et al. Early interventions for youths at high risk for bipolar disorder: a developmental approach Eur Child Adolesc Psychiatry 2016 25 217 233
60. Frías Á Palma C Farriols N Comorbidity in pediatric bipolar disorder: prevalence, clinical impact etiology and treatment J Affect Disord 2015 174 378 389
61. Cadenhead K S Addington J Cannon T et al. Treatment history in the psychosis prodrome: characteristics of the North American Prodrome Longitudinal Study Cohort Early Interv Psychiatry 2010 4 220 226
62. Velthorst E Nieman D H Becker H E et al. Baseline differences in clinical symptomatology between ultra-high-risk subjects with and without a transition to psychosis Schizophr Res 2009 109 60 65
63. McGorry P D Yung A R Phillips L J et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms Arch Gen Psychiatry 2002 59 921 928
64. Phillips L J McGorry P D Yuen H P et al. Medium-term follow-up of a randomized controlled trial of interventions for young people at ultra-high risk of psychosis Schizophr Res 2007 96 25 33
65. McGlashan T H Zipursky R B Perkins D et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis Am J Psychiatry 2006 163 790 799
66. Woods S W Breier A Zipursky R B et al. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome Biol Psychiatry 2003 54 453 464
67. McGorry P D Nelson B Phillips L J et al. Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome J Clin Psychiatry 2013 74 349 356
68. Yung A R Phillips L J Nelson B et al. Randomized controlled trial of interventions for young people at ultra-high risk for psychosis: 6-month analysis J Clin Psychiatry 2011 72 430 440
69. Phillips L J Nelson B Yuen H P et al. Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: study design and baseline characteristics Aust N Z J Psychiatry 2009 43 818 829
70. Ruhrmann S Bechdolf A Kühn K U Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis Br J Psychiatry 2007 51 88 95
71. Woods S W Tully E M Walsh B C et al. Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study Br J Psychiatry 2007 51 96 101
72. Kobayashi H Morita K Takeshi K et al. Effects of aripiprazole on insight and subjective experience in individuals with an at-risk mental state J Clin Psychopharmacol 2009 29 421 425
73. Walker E F Cornblatt B A Addington J et al. The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: a naturalistic study of the North American Prodromal Longitudinal Sample Schizophr Res 2009 115 50 57
74. Liu C C Chien Y L Hsieh M H et al. Aripiprazole for drug-naive or antipsychotic-short-exposure subjects with ultra-high risk state and first-episode psychosis: an open-label study J Clin Psychopharmacol 2013 33 18 23
75. Washida K Takeda T Habara T et al. Efficacy of second-generation antipsychotics in patients at ultra-high risk and those with first-episode or multi-episode schizophrenia Neuropsychiatr Dis Treat 2013 9 861 868
76. Tsujino N Nemoto T Morita K et al. Long-term efficacy and tolerability of perospirone for young help-seeking people at clinical high risk: a preliminary open trial Clin Psychopharmacol Neurosci 2013 211 132 136
77. Stafford M R Jackson H Mayo-Wilson E et al. Early interventions to prevent psychosis: systematic review and meta-analysis BMJ 2013 346 185
78. van der Gaag M Smit F Bechdolf A et al. Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups Schizophr Res 2013 149 56 62
79. Amminger G P Schäfer M R Papageorgiou K et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial Arch Gen Psychiatry 2010 67 146 154
80. Woods S W Walsh B C Hawkins K A et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies Eur Neuropsychopharmacol 2013 23 931 940
81. Cornblatt B A Lencz T Smith C W et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents J Clin Psychiatry 2007 68 546 557
82. Amminger G P Schäfer M R Schlögelhofer M et al. Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study Nat Commun 2015 6 7934
83. Markulev C McGorry P D Nelson B et al. NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra-high risk of schizophrenia and other psychotic disorders Early Interv Psychiatry 2015 10.1111/eip.12260 [Epub ahead of print]
84. McGorry P D Goldstone S Berger G et al. The NEURAPRO-E study: a multicentre RCT of omega-3 fatty acids and cognitive-behavioral case management for patients at ultra-high risk of psychosis Oral Poster presentation SIRS 2016 - npj Schizophrenia Abstracts (attached-page 24) http://www.nature.com/npjschz/abstracts
85. Fusar-Poli P Valmaggia L McGuire P Can antidepressants prevent psychosis? Lancet 2007 370 1746 1748
86. Simon A E Velthorst E Nieman D H et al. Ultra-high-risk state for psychosis and non-transition: a systematic review Schizophr Res 2011 132 8 17
87. Geller B Cooper T B Zimerman B et al. Lithium for prepubertal depressed children with family history predictors of future bipolarity: a double-blind, placebo-controlled study J Affect Disord 1998 51 165 175
88. Chang K D Dienes K Blasey C et al. Divalproex monotherapy in the treatment of bipolar offspring with mood and behavioral disorders and at least mild affective symptoms J Clin Psychiatry 2003 64 936 942
89. Findling R L Frazier T W Youngstrom E A et al. Double-blind, placebo-controlled trial of divalproex monotherapy in the treatment of symptomatic youth at high risk for developing bipolar disorder J Clin Psychiatry 2007 68 781 788
90. DelBello M P Adler C M Whitsel R M et al. A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder J Clin Psychiatry 2007 68 789 795
91. McNamara R K Nandagopal J J Strakowski S M et al. Preventative strategies for early-onset bipolar disorder: towards a clinical staging model CNS Drugs 2010 24 983 996
92. Sarris J Mischoulon D Schweitzer I Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression J Clin Psychiatry 2012 73 81 86
93. De Hert M Detraux J van Winkel R et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs Nat Rev Endocrinol 2011 8 114 126
94. Correll C U Antipsychotic use in children and adolescents: Minimizing adverse effects to maximize outcomes J Am Acad Child Adolesc Psychiatry 2008 47 9 20
95. Aderhold V Weinmann S Hägele C et al. Can long-term treatment with antipsychotic drugs lead to structural brain damage? Nervenarzt 2013 84 1117 1119
96. Aderhold V Weinmann S Hägele C et al. Frontal brain volume reduction due to antipsychotic drugs? Nervenarzt 2015 86 302 323
97. Fusar-Poli P Smieskova R Kempton M J et al. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies Neurosci Biobehav Rev 2013 37 1680 1691
98. Szöke A Trandafir A Dupont M E et al. Longitudinal studies of cognition in schizophrenia: meta-analysis Br J Psychiatry 2008 192 248 257
99. Nielsen R E Levander S Kjaersdam Telleus G et al. Second-generation antipsychotic effect on cognition in patients with schizophrenia - a meta-analysis of randomized clinical trials Acta Psychiatr Scand 2015 131 185 196
100. Lesh T A Tanase C Geib B R et al. A multimodal analysis of antipsychotic effects on brain structure and function in first-episode schizophrenia JAMA Psychiatry 2015 72 226 234
101. Andreasen N C Liu D Ziebell S et al. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study Am J Psychiatry 2013 170 609 615
102. Compton M T Kelley M E Ramsay C E et al. Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients Am J Psychiatry 2009 166 1251 1257
103. Correll C U Robinson D G Schooler N R et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study JAMA Psychiatry 2014 71 1350 1363
104. Lambert M Bock T Naber D et al. Mental health of children, adolescents and young adults - part 1: prevalence, illness persistence, adversities, service use, treatment delay and consequences Fortschr Neurol Psychiatr 2013 81 614 627
105. Lambert M Schöttle D Sengutta M et al. Early detection and integrated care in adolescents and young adults with severe psychotic illnesses Psychiatr Prax 2015 42 01 49 53
106. Zito J M Derivan A Kratochvil C et al. Off-label psychopharmacologic prescribing for children: History supports close clinical monitoring Child Adolesc Psychiatry Ment Health 2008 2 24 35
107. Amor L Antipsychotics in pediatric and adolescent patients: a review of comparative safety data J Affect Disord 2012 138 Suppl 22 30
108. Whitney Z Boyda H N Procyshyn R M et al. Therapeutic drug levels of second generation antipsychotics in youth: a systematic review J Child Adolesc Psychopharmacol 2015 25 234 245
109. Caccia S Clavenna A Bonati M Antipsychotic drug toxicology in children Expert Opin Drug Metab Toxicol 2011 7 591 608
110. Gonzalez-Martin G Caroca C M Paris E Adverse drug reactions (ADRs) in hospitalized pediatric patients. A prospective study. Int J Clin Pharmacol Ther 1998 36 530 533
111. De Hert M Dobbelaere M Sheridan E M et al. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice Eur Psychiatry 2011 26 144 158
112. Agius M Butler S Rationale for clinical interventions in prodromal psychosis Are such interventions safe? Psychiatr Danub 2012 24 01 28 35
113. Isojarvi I Jaatikainen T J Pakarinen A J et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy N Engl J Med 1993 329 1383 1388
114. Morrison A P French P Walford L et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial Br J Psychiatry 2004 185 291 297
115. Morrison A P French P Parker S et al. Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk Schizophr Bull 2007 33 682 687
116. Addington J Epstein I Liu L et al. A randomized controlled trial of cognitive-behavioral therapy for individuals at CHR of psychosis Schizophr Res 2011 125 54 61
117. van der Gaag M Nieman D H Rietdijk J et al. Cognitive-behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial Schizophr Bull 2012 38 1180 1188
118. Hooker C I Carol E E Eisenstein T J et al. A pilot study of cognitive training in CHR for psychosis: initial evidence of cognitive benefit Schizophr Res 2014 157 314 316
119. O’Brien M P Zinberg J L Bearden C E et al. Psycho-educational multi-family group treatment with adolescents at high risk for developing psychosis Early Interv Psychiatry 2007 1 325 332
120. Miklowitz D J O’Brien M P Schlosser D A et al. Family-focused treatment for adolescents and young adults at high risk for psychosis: results of a randomized trial J Am Acad Child Adolesc Psychiatry 2014 53 848 858
121. Bechdolf A Wagner M Ruhrmann S et al. Preventing progression to first-episode psychosis in early initial prodromal states Br J Psychiatry 2012 200 22 29
122. Pfennig A Correll C U Marx C et al. Psychotherapeutic interventions in individuals at risk of developing bipolar disorder: a systematic review Early Interv Psychiatry 2014 8 3 11
123. Nadkarni R B Fristad M A Clinical course of children with a depressive spectrum disorder and transient manic symptoms Bipolar Disord 2010 12 494 503
124. Miklowitz D J Chang K D Taylor D O et al. Early psychosocial intervention for youth at risk for bipolar I or II disorder: a one-year treatment development trial Bipolar Disord 2011 13 67 75
125. Miklowitz D J Schneck C D Singh M K et al. Early intervention for symptomatic youth at risk for bipolar disorder: a randomized trial of family-focused therapy J Am Acad Child Adolesc Psychiatry 2013 52 121 131
126. Goldstein T R Fersch-Podrat R Axelson D A et al. Intervention for adolescents at high risk for the development of bipolar disorder: pilot study of Interpersonal and Social Rhythm Therapy (IPSRT) Psychotherapy 2014 51 180 189
127. Pfennig A Leopold K Bechdolf A et al. Early specific cognitive-behavioural psychotherapy in subjects at high risk for bipolar disorders: study protocol for a randomised controlled trial Trials 2014 15 161
128. Karow A Bock T Naber D et al. Mental health of children, adolescents and young adults - part 2: burden of illness, deficits of the German health care system and efficacy and effectiveness of early intervention services Fortschr Neurol Psychiatr 2013 81 628 638
129. Green H McGinnity A Meltzer H et al. Mental Health of Children and Young People in Great Britain Basingstoke, Hampshire Palgrave Macmillan 2004 Available from URL http://www.hscic.gov.uk/catalogue/PUB06116/ment-heal-chil-youn-peop-gb-2004-rep2.pdf
130. Burgess P M Pirkis J E Slade T N et al. Service use for mental health problems: findings from the 2007 National Survey of Mental Health and Wellbeing Aus N ZJ Psychiatry 2009 43 615 623
131. Alonso J Angermeyer M C Bernert S et al. Use of mental health services in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project Acta Psychiatrica Scandinavica Supplement 2004 420 47 54
132. Smith T E Easter A Pollock M et al. Disengagement from care: perspectives of individuals with serious mental illness and of service providers Psychiatr Serv 2013 64 770 775
133. Evans-Lacko S dosReis S Kastelic E et al. Mental health service use before and after diagnosis of early-onset bipolar disorder J Behav Health Serv Res 2011 38 398 413
134. Leopold K Nikolaides A Bauer M et al. Services for the early recognition of psychoses and bipolar disorders in Germany: inventory survey study Nervenarzt 2015 86 352 358
135. McGrath J J Susser E S New directions in the epidemiology of schizophrenia Med J Aust 2009 190 4 Suppl 7 9
136. Kirkbride J B Errazuriz A Croudace T J et al. Incidence of schizophrenia and other psychoses in England, 1950-2009: a systematic review and meta-analyses PLoS One 2012 7 31660
137. Kennedy N Everitt B Boydell J et al Incidence and distribution of first-episode mania by age: results from a 35-year study Psychol Med 2005 35 855 863
138. Kearns M A Hawley K M Predictors of polypharmacy and off-label prescribing of psychotropic medications: a national survey of child and adolescent psychiatrists J Psychiatr Pract 2014 20 438 447
139. Roberts R Rodriguez W Murphy D et al. Pediatric drug labeling JAMA 2003 290 905 911
140. Gerstenberg M Theodoridou A Traber-Walker N et al. Adolescents and adults at clinical high-risk for psychosis: age-related differences in attenuated positive symptoms syndrome prevalence and entanglement with basic symptoms Psychol Med 2016 46 1069 1078
141. Gerstenberg M Hauser M Al-Jadiri A et al. Frequency and correlates of DSM-5 attenuated psychosis syndrome in a sample of adolescent inpatients with nonpsychotic psychiatric disorders J Clin Psychiatry 2015 76 e1449 e1458
142. Lo Cascio N Saba R Hauser M et al. Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis Eur Child Adolesc Psychiatry 2016 [Epub ahead of print]
143. Hauser M Correll C U The significance of at-risk or prodromal symptoms for bipolar I disorder in children and adolescents Can J Psychiatry 2013 58 22 31
144. Correll C U Sheridan E M DelBello M P Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials Bipolar Disord 2010 12 116 141
145. Gerlinger G Hauser M De Hert M et al. Personal stigma in schizophrenia spectrum disorders: a systematic review of prevalence rates, correlates, impact and interventions World Psychiatry 2013 12 155 164